Lupin's Tarapur facility gets OAI
Lupin announced that the inspection by United States Food and Drug Administration (USFDA) at the company’s manufacturing facility in Tarapur concluded with Official Action Indicated (OAI).
The company’s facility at Tarapur is an Active Pharmaceutical Ingredient (APIs) manufacturing facility. The inspection at the facility took place from September 16 to 20, 2019. The inspection closed with three observations. According to the company, the inspection results will not impact and cause disruptions of supplies or existing revenue from the operations at the respective facility. Lupin intends to reply to the conclusion with further corrective actions and updates.
Lupin is an innovation-led transnational pharmaceutical company, developing and delivering a wide range of branded and generic formulations, biosimilar products, and APIs, globally. It is considered to be a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, Gl, Anti-Infective, NSAID areas and holds a global leadership position in the Anti-TB segment as well.
On Monday, the stock of the company closed at Rs 749.95, down by 1.19 per cent or Rs 9.05 per share. The intraday high was Rs 764 and intraday low was Rs 740.60. The 52-week high is Rs 887.70 and 52-week low is Rs 646.20 on the BSE.